Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female aged 15 years and over (≥18 years in United Kingdom and South Africa), with at least a 12 month documented history of experiencing migraine according to IHS criteria, including confirmation of a 3 month diary based documented history of MAM.~* An average frequency of MAM in at least two out of three menstrual cycles, within the previous 12 months~* Regular, predictable menstrual periods~* MAM headaches occurring between Day -2 and day +4 of menses~* Able and willing to sign informed consent and to comply with study procedures, including completion of the diary cards.~Exclusion Criteria:~* More than three migraine attacks per month that were not MAM attacks~* A history of myocardial infarction, ischemic heart disease (or presenting with symptoms or signs compatible with ischemic heart disease), coronary vasospasm or peripheral vascular disease~* Significant cerebrovascular disease including basilar or hemiplegic migraine~* Uncontrolled hypertension (SBP \>180 mmHg, DBP \>95 mmHg)~* Severe hepatic or renal insufficiency~* More than 15 headache days per month, exclusive of migraine headache~* Any other condition or serious illness which, in the opinion of the investigator, would interfere with optimal participation in the study~* A history of clinically relevant allergy, including that to frovatriptan or other triptans~* Pregnant or breast-feeding, or intending to become pregnant or breast-feed during the study period (patients were to be using adequate contraception and have a negative pregnancy test at screening)~* Treatment with another investigational drug within 30 days or 5 half-lives (whichever was longer) before the screening visit~* Any change in their oral contraceptive medication (if applicable) in the 2 months prior to screening, or anticipation of any change during study participation~* Any change in the type or dose of any prophylactic migraine medication in the 2 months prior to screening, or anticipation of any change during study participation~* A history of migraine with aura, according to IHS criteria, and currently treated with a combined oral contraceptive (South Africa only).

- Gender: FEMALE
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Frovatriptan 2.5 mg (Type: EXPERIMENTAL): Frovatriptan 2.5 mg tablets administered orally 2 x 2.5 mg twice daily (loading dose) on day 1, followed by 2.5 mg twice daily days 2 to 6.

Based on this trial design, predict the completion outcome and termination type (if applicable).